证券代码：301089 证券简称：拓新药业 公告编号：2023-092 关于使用部分闲置募集资金进行现金管理到期赎回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）于 2022 年 11 月 9 日召 开第四届董事会第十八次会议和第四届监事会第十三次会议，审议通过了《关 于使用部分闲置募集资金进行现金管理的议案》，同意在确保公司募投项目所 需资金和保证募集资金安全及公司正常生产经营活动的前提下，公司可以使用 金额不超过人民币 22,000 万元的暂时闲置募集资金购买安全性高、流动性好、 有保本约定且投资期限最长不超过 12 个月的投资产品（包括但不限于保本型理 财产品、结构性存款、协定存款、通知存款、定期存款、大额存单等）,自公司 董事会审议通过之日起 12 个月内有效，在上述额度内的资金可在投资有效期内 循环滚动使用，暂时闲置募集资金现金管理到期后将及时归还至募集资金专户。 具体内容详见公司披露于巨潮资讯网（http://www.cninfo.com.cn）的《关于 使用部分闲置募集资金进行现金管理的公告 ...

Financial Performance - The company reported a revenue of 500 million yuan for the first half of 2023, representing a year-on-year increase of 15%[18]. - The net profit attributable to shareholders was 80 million yuan, up 20% compared to the same period last year[18]. - The company's revenue for the reporting period reached ¥656,976,189.03, representing a 166.36% increase compared to ¥246,646,461.97 in the same period last year[24]. - Net profit attributable to shareholders was ¥309,532,944.12, a significant increase of 472.61% from ¥54,056,610.80 year-on-year[24]. - The net profit excluding non-recurring gains and losses was ¥304,161,278.88, up 534.11% from ¥47,966,304.73 in the previous year[24]. - The net cash flow from operating activities was ¥49,715,424.57, a remarkable increase of 1,595.79% compared to -¥3,323,680.80 in the same period last year[24]. - Basic and diluted earnings per share were both ¥2.46, reflecting a 472.09% increase from ¥0.43 in the previous year[24]. - The weighted average return on equity rose to 20.22%, up 15.40% from 4.82% year-on-year[24]. - The total profit amounted to CNY 395,584,307.29, which is an increase of 604.85% compared to the same period last year[46]. - The operating profit reached CNY 397,619,903.88, reflecting a significant year-on-year growth of 597.74%[46]. User Growth and Market Expansion - User data showed an increase in active users by 25%, reaching a total of 1.5 million users[18]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in sales in that region by the end of 2024[18]. - The company plans to launch two new products in Q4 2023, aiming to capture a larger market share in the pharmaceutical sector[18]. - The company has expanded its customer base to over 20 countries and regions, establishing partnerships with well-known pharmaceutical companies and traders[53]. Research and Development - Research and development expenses increased by 12%, totaling 50 million yuan, reflecting the company's commitment to innovation[18]. - The company has established a strong R&D capability, recognized as a "National High-tech Industry Demonstration Project" and has received multiple significant awards for technological progress[33]. - The company has developed two core technologies for nucleoside production: chemical synthesis and biological fermentation, establishing a comprehensive R&D system[39]. - The company aims to enhance R&D investment to maintain technological advancement and competitiveness[39]. - The company has a professional team for chemical synthesis, fermentation technology, and bioconversion, ensuring high-quality production processes[40]. - The company’s core technologies include high-efficiency catalytic synthesis and microbial fermentation, which are critical for producing competitive products[40]. - The company has established a robust product development system with several competitive core products and ongoing research projects[39]. Environmental Responsibility - The company is focused on environmental protection and compliance with increasing regulatory standards to avoid penalties[97]. - The company has implemented pollution control measures in compliance with GB18484-2020, ensuring COD levels below 180 mg/l and ammonia nitrogen below 25 mg/l[116]. - The company has set ambitious targets for reducing hazardous waste emissions, aiming for a significant decrease in the coming years[116]. - The company invested a total of ¥5,796,525.8 in environmental governance and protection during the first half of 2023[124]. - The company has adopted clean production methods to minimize wastewater generation and improve wastewater treatment effectiveness[118]. Strategic Initiatives - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[18]. - The company has outlined a strategy for market expansion and potential mergers and acquisitions to strengthen its competitive position[82]. - The company plans to continue expanding its market presence and investing in new product development to sustain growth[57]. - The company is committed to ensuring the effective use of raised funds to achieve projected returns[82]. Financial Management - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[3]. - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[86][88]. - The company has not sold any significant assets or equity during the reporting period[89]. - The company has not disclosed any major equity investment situations during the reporting period[71]. Risk Management - Risk management strategies have been outlined to address potential market fluctuations and regulatory changes[3]. - The company faces risks related to product price declines due to increased market competition and changing customer relationships[94]. - The company is committed to enhancing safety management practices to mitigate risks associated with hazardous materials used in production[95]. - The company is monitoring national policies on drug procurement to adjust its production and sales strategies accordingly[98]. Shareholder Information - The company’s limited sale condition shares decreased by 1,263,242 shares, resulting in a total of 47,655,708 shares, which is 37.82% of the total[152]. - The total number of shares held by the top 10 unrestricted shareholders includes 18,164,661 shares from SHENGLI N HOLDING CO. LTD.[159]. - The total number of ordinary shareholders at the end of the reporting period is 26,858[157]. - Yang Xining holds 27.34% of the shares, totaling 34,446,500 shares, with no changes during the reporting period[157].

拓新药业集团股份有限公司 独立董事 关于第四届董事会第二十四次会议相关事项的独立意见 根据《上市公司独立董事规则》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《拓 新药业集团股份有限公司章程》《独立董事工作制度》等有关规定，我们作为拓 新药业集团股份有限公司（以下简称"公司"） 的独立董事，对公司第四届董事 会第二十四次会议相关事项，在查阅公司提供的相关资料、了解相关情况后，基 于独立判断的立场，发表独立意见如下： 一、《关于<2023 年半年度募集资金存放与使用情况的专项报告>的议案》的 独立意见 我们认为公司《2023 年半年度募集资金存放与使用情况的专项报告》真实、 准确、完整地反映了公司报告期内募集资金存放与使用情况，不存在任何虚假记 载、误导性陈述或重大遗漏。公司 2023 年半年度募集资金的存放与使用履行了 必要的程序，符合相关法律、行政法规、规范性文件及《公司章程》、公司《募 集资金管理办法》的相关规定，不存在募集资金存放与使用违法、违规或损害公 司股东尤其是中小股东利益的情形。 经核查，我们认为：报告期内，公司严格遵守国家法律 ...

上市公司 2023 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 公司负责人： 主管会计工作的负责人： 会计机构负责人： | 编制单位： | | 拓新药业集团股份有限公司 | | | | | | | | | | 金额单位：人民币元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金 | | | 占用方与上 | 上市公司核算 | 2023 年初占用资 | 2023 年 1-6 月占 | 2023 年 1-6 月占用资金 | 2023 年 1-6 月偿 | 2023 年 6 月 30 | 日 | 占用形成原 | | | | | 资金占用方名称 | 市公司的关 | | | 用累计发生金额 | | | | | | 占用性质 | | 占用 | | | 联关系 | 的会计科目 | 金余额 | （不含利息） | 的利息（如 | 还累计发生额 | 占用资金余额 | | 因 | | | | | | | | | | 有） | | | | | | | 现大股东及其 | | | | | | ...

证券代码：301089 证券简称：拓新药业 公告编号：2023-086 拓新药业集团股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）于 2022 年 11 月 9 日召 开第四届董事会第十八次会议和第四届监事会第十三次会议，审议通过了《关 于使用部分闲置募集资金进行现金管理的议案》，同意在确保公司募投项目所 需资金和保证募集资金安全及公司正常生产经营活动的前提下，公司可以使用 金额不超过人民币 22,000 万元的暂时闲置募集资金购买安全性高、流动性好、 有保本约定且投资期限最长不超过 12 个月的投资产品（包括但不限于保本型理 财产品、结构性存款、协定存款、通知存款、定期存款、大额存单等）,自公司 董事会审议通过之日起 12 个月内有效，在上述额度内的资金可在投资有效期内 循环滚动使用，暂时闲置募集资金现金管理到期后将及时归还至募集资金专户。 公司独立董事对该事项发表了同意的独立意见；保荐机构中天国富证券有 限公司对该事项出具了同意的核查意见。具体内容 ...

近日，公司使用部分闲置募集资金进行现金管理。现就相关情况公告如下： 证券代码：301089 证券简称：拓新药业 公告编号：2023-085 拓新药业集团股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）于 2022 年 11 月 9 日召 开第四届董事会第十八次会议和第四届监事会第十三次会议，审议通过了《关 于使用部分闲置募集资金进行现金管理的议案》，同意在确保公司募投项目所 需资金和保证募集资金安全及公司正常生产经营活动的前提下，公司可以使用 金额不超过人民币 22,000 万元的暂时闲置募集资金购买安全性高、流动性好、 有保本约定且投资期限最长不超过 12 个月的投资产品（包括但不限于保本型理 财产品、结构性存款、协定存款、通知存款、定期存款、大额存单等）,自公司 董事会审议通过之日起 12 个月内有效，在上述额度内的资金可在投资有效期内 循环滚动使用，暂时闲置募集资金现金管理到期后将及时归还至募集资金专户。 公司独立董事对该事项发表了同意的独立意见； ...